ABCL Stock Risk & Deep Value Analysis
Abcellera Biologics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ABCL Stock
We analyzed Abcellera Biologics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ABCL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ABCL Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is clinical trial failure for ABCL635. If Phase 2 results are not compelling, or if regulatory hurdles delay progression, the primary near-term catalyst for revenue diversification and market re-rating will be severely undermined, leading to potential significant stock price depreciation and ongoing cash burn pressures.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Persistent negative net margins and high cash burn, leading to continued dependence on capital markets.
- ⚠
Significant revenue concentration from a few partnerships or milestone payments, leading to revenue volatility.
- ⚠
Long drug development cycles mean high R&D spend without immediate returns, straining financials.
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for ABCL635 or other candidates
- 📅
Higher-than-expected cash burn and need for dilutive financing
When to Reconsider
- 🚪
Exit if ABCL635 Phase 2 results in Q3 2026 are negative or significantly delayed.
- 🚪
Sell if the company announces a highly dilutive capital raise (e.g., >20% share dilution) without commensurate pipeline progress.
- 🚪
Exit if quarterly revenue growth stagnates or declines for two consecutive quarters, indicating a slowdown in partnership traction.
Unlock ABCL Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Abcellera Biologics Inc (ABCL) Do?
Market Cap
$1.19B
Sector
Healthcare
Industry
Biotechnology
Employees
596
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Visit Abcellera Biologics Inc WebsiteInvestment Thesis
AbCellera is a high-growth, high-risk investment positioned at the intersection of AI and biologics. Its proprietary platform offers a significant competitive edge in antibody discovery, while its evolving strategy to develop internal therapeutics like ABCL635 (for menopause) provides direct upside potential through future royalties. Positive clinical trial data and continued partnership expansion could lead to substantial value creation over 3-5 years, fulfilling its 10x growth potential.
Is ABCL Stock Undervalued?
Unlock the full AI analysis for ABCL
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ABCL Price Targets & Strategy
12-Month Target
$10.00
Bull Case
$15.00
Bear Case
$2.50
Valuation Basis
Based on 15x forward P/S applied to estimated FY2026 revenue of $200M, implying a $3.0B Market Cap, divided by ~305M shares outstanding.
Entry Strategy
Dollar-cost average between $3.50-$4.00, leveraging recent support zones and ahead of the Q1 earnings call and ABCL635 data disclosures.
Exit Strategy
Take partial profits at $10.00 (analyst target) and scale out towards $15.00 upon significant positive clinical trial results; Stop-loss at $2.80 (break of multi-month support).
Portfolio Allocation
5% for aggressive risk tolerance, given the early-stage pipeline and negative profitability.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ABCL Financially Healthy?
Valuation
P/E Ratio
-8.00
Price/Book
1.40
Price/Sales
43.04
Profitability
Operating Margin
-288.98%
Net Margin
-194.89%
Return on Equity
-14.79%
Revenue Growth
160.55%
EPS
$-0.49
Balance Sheet
Current Ratio
11.32
Quick Ratio
11.08
Debt/Equity
0.15
Cash Flow
EBITDA
-$218.38M
Other
Beta (Volatility)
0.97
Does ABCL Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is strengthening as AbCellera's AI platform generates more data, improves its predictive power, and yields successful clinical candidates, increasing its lead over competitors. The unique biological insights gained through its discovery process are difficult to replicate.
Moat Erosion Risks
- •Emergence of superior AI discovery platforms or technologies from well-funded competitors.
- •Difficulty in translating preclinical success into clinical efficacy, eroding confidence in the platform's predictive power.
ABCL Competitive Moat Analysis
Sign up to see competitive advantages
ABCL Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, with growing interest post-Q4 earnings and ABCL635 news.
Institutional Sentiment
Neutral to Positive, with Truist reiterating Buy and a $10 target, offsetting a general consensus of 'Hold'. High institutional ownership (61.42%) indicates long-term conviction.
Insider Activity (Form 4)
No specific Form 4 filings reported in the last 90 days. Institutional ownership at 61.42% as of Q3 2025.
Options Flow
Normal options activity, reflecting mixed sentiment ahead of earnings and clinical data, no unusual block trades detected.
Earnings Intelligence
Next Earnings
2026-05-11
Surprise Probability
Medium, given the significant Q4 2025 beat and the importance of ABCL635 data disclosure during the call.
Historical Earnings Pattern
Historically, the stock has shown volatility around earnings, reacting strongly to revenue beats/misses and updates on pipeline progress. Q4 2025 earnings saw a significant beat, which likely triggered positive reaction.
Key Metrics to Watch
Competitive Position
Top Competitor
SDGR (Schrödinger, Inc.)
Market Share Trend
Gaining ground in the AI-powered antibody discovery space, evidenced by successful partnerships and pipeline advancement.
Valuation vs Peers
Trading at a premium on enterprise value to sales (EV/S) compared to some platform biotechs, reflecting its unique AI antibody discovery IP and clinical pipeline potential.
Competitive Advantages
- •Proprietary AI-powered antibody discovery platform with high throughput and efficiency
- •Integrated approach from discovery to clinical development, controlling more of the value chain
- •Strategic focus on developing novel, first-in-class therapeutics like ABCL635
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ABCL Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Call (May 11, 2026) with disclosure of interim Phase 1 data for ABCL635
- •Potential new antibody discovery partnership announcements
Medium-Term (6-18 months)
- •Phase 2 results for ABCL635 (expected Q3 2026)
- •Advancement of other pipeline candidates into clinic
Long-Term (18+ months)
- •Approval and commercialization of ABCL635, generating significant royalty revenue
- •Establishment as a dominant AI-powered drug discovery and development partner
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ABCL?
- ✓
Acceleration in royalty or milestone revenue from partnered programs.
- ✓
Strong safety and efficacy data from ABCL635 Phase 2 trials.
Bull Case Analysis
See what could go right with Premium
Competing with ABCL
See how Abcellera Biologics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Abcellera Biologics Inc ABCL | $1.2B | 7.2 | -8.0 | $32.9M | -194.9% | 160.6% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Abcellera Biologics Inc Makes Money
AbCellera makes money by leveraging its advanced AI and machine learning platform to discover antibodies for drug development. It partners with pharmaceutical and biotech companies, earning upfront research fees, milestone payments as drug candidates progress through clinical trials, and potential royalties on the sales of successful, approved drugs. The company is also increasingly developing its own therapeutic candidates, such as ABCL635, to capture a larger share of the value created by its platform.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Abcellera Biologics Inc (ABCL)?
As of April 21, 2026, Abcellera Biologics Inc has a DVR Score of 7.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Abcellera Biologics Inc?
Abcellera Biologics Inc's market capitalization is approximately $1.2B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Abcellera Biologics Inc use?
ABCL is the ticker symbol for Abcellera Biologics Inc. The company trades on the NMS.
What is the risk level for ABCL stock?
Our analysis rates Abcellera Biologics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ABCL?
Abcellera Biologics Inc currently has a price-to-earnings (P/E) ratio of -8.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Abcellera Biologics Inc's revenue growing?
Abcellera Biologics Inc has reported revenue growth of 160.6%. The company is showing strong top-line momentum.
Is ABCL stock profitable?
Abcellera Biologics Inc has a profit margin of -194.9%. The company is currently unprofitable.
How often is the ABCL DVR analysis updated?
Our AI-powered analysis of Abcellera Biologics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ABCL (Abcellera Biologics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.